October 2015

Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but also could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.

The discount drug program intended for safety-net hospitals and special AIDS clinics has mushroomed even more than earlier reports have suggested, with oncology drugs fueling much of the growth, according to a new report commissioned by community oncology providers.

A combination of cytoreductive surgical resection and hyperthermic intraperitoneal chemotherapy-sometimes referred to as "hot chemotherapy bath"-has the potential to provide some patients with long-term survival.

Bioinformatics research has developed rapid, increasingly specific, and cost-effective tools to analyze and interpret health information.

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

The impact upon cancer care, made by Paul Bunn, MD, extends far beyond the programs he helped build in Colorado.

Less than a decade after the FDA set the ground rules for developing assays that pair molecular targets with new drugs, experts say there have been strides in personalizing anticancer therapies but that many hurdles remain before next-generation sequencing and other precision medicine advances are incorporated into the diagnostic paradigm.

The Hedgehog pathway is one of several key developmental cell-signaling networks whose aberrant activation in adult tissues can lead to cancer.

The use of multigene assays to screen patients for hereditary breast and ovarian cancer risk yields clinically valuable information beyond single-gene BRCA testing, but confusion about accurately interpreting the results presents a challenge for clinicians even as panel testing becomes more widely adopted.

Determining the best course of treatment for sarcomas of the bone and soft tissues is a complex process.

The evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.

The data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.

There are many reasons, why we must now move beyond the "one drug-one test" model that has resulted in these diagnostics.

Examples of the clinical relevance of an individual patient's normal polymorphisms continue to mount.